Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583253 | 0.88 | P2RX7 (0.46) | P2RX7NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL12125488 | 0.88 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL1583540 | 0.85 | CNR2 (0.40) | P2RX7NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL4005175 | 0.85 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL21063418 | 0.85 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL6873040 | 0.85 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL24744821 | 0.84 | NR1H2 (0.40) | P2RX7NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL31570956 | 0.84 | TSHR (0.44) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL4392562 | 0.84 | ALDH1A1 (0.43) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL17691085 | 0.84 | DDB1 (0.41) | NR1H2USP2SMN1; SMN2ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181567-B9 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-116462664-A | Pyrazole ring compound, preparation method, composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-22 | — | — | US | disclosed |
| CN-107098886-B | Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-07-14 | — | — | CN | disclosed |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3181567-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-108822048-A | The synthesis technology of 4- (- 4,7 diazaspiracyclic of 4- ethyl [3,3] octyl) -2- nitroaniline | 上海昌肽生物科技有限公司 | 2018-11-16 | — | — | CN | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| CN-101001852-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-07-18 | — | — | CN | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-0882041-B1 | PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | EP | disclosed |
| US-6069145-A | AGAINST ANTIBIOTIC RESISTANT BACTERIA | ZENECA LIMITED (GB) | 2000-05-30 | — | — | US | disclosed |
| EP-0882041-A1 | PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997027188-A1 | PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | BTK, LCK, SYK | P2RX7 497/4885NR1H2 4135/4885USP2 4271/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | P2RX7 126/4885NR1H2 1727/4885USP2 3692/4885 |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | P2RX7 4277/4885NR1H2 171/4885USP2 133/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | P2RX7 2871/4885NR1H2 1770/4885USP2 3366/4885 |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | BTK, SYK, LCK | P2RX7 421/4885NR1H2 4404/4885USP2 4536/4885 |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | BTK, SYK, LCK | P2RX7 421/4885NR1H2 4404/4885USP2 4536/4885 |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | BTK, LCK, LYN | P2RX7 670/4885NR1H2 4528/4885USP2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.